1-(2,2-difluoroethyl)piperidin-4-one | 1178833-49-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-(2,2-difluoroethyl)piperidin-4-one
• CAS: 1178833-49-2
• 化学式: C₇H₁₁F₂NO
• mdl: MFCD12768588
• 分子量: 163.167
• InChiKey: DYLIPBUMUVWHAZ-UHFFFAOYSA-N

物化性质

• 沸点：
  215.0±40.0 °C(Predicted)
• 密度：
  1.142±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.857
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(2,2-difluoroethyl)piperidin-4-one 在 4-二甲氨基吡啶 、 palladium 10% on activated carbon 、 甲基溴化镁 、 氢气 、 对甲苯磺酸 作用下， 以 四氢呋喃 、 甲醇 、 乙醚 、 甲苯 为溶剂， 反应 6.5h， 生成 6-[1-(2,2-difluoroethyl)-4-piperidyl]-2-oxo-N-(4-phenylbutyl)-1,3-benzoxazole-3-carboxamide
  参考文献：
  名称：

  Lead Optimization of Benzoxazolone Carboxamides as Orally Bioavailable and CNS Penetrant Acid Ceramidase Inhibitors

  摘要：

  Sphingolipids (SphLs) are a diverse class of molecules that are regulated by a complex network of enzymatic pathways. A disturbance in these pathways leads to lipid accumulation and initiation of several SphL-related disorders. Acid ceramidase is one of the key enzymes that regulate the metabolism of ceramides and glycosphingolipids, which are important members of the SphL family. Herein, we describe the lead optimization studies of benzoxazolone carboxamides resulting in piperidine 22m, where we demonstrated target engagement in two animal models of neuropathic lysosomal storage diseases (LSDs), Gaucher's and Krabbe's diseases. After daily intraperitoneal administration at 90 mg kg(-1), 22m significantly reduced the brain levels of the toxic lipids glucosylsphingosine (GluSph) in 4L;C* mice and galactosylsphingosine (GalSph) in Twitcher mice. We believe that 22m is a lead molecule that can be further developed for the correction of severe neurological LSDs where GluSph or GalSph play a significant role in disease pathogenesis.

  DOI：

  10.1021/acs.jmedchem.9b02004

文献信息

• BICYCLIC AZA HETEROCYCLES, AND USE THEREOF
  申请人：Follmann Markus

  公开号：US20140148433A1

  公开（公告）日：2014-05-29

  The present application relates to novel bicyclic azaheterocycles, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of cardiovascular disorders.

  本申请涉及新型的双环氮杂杂环化合物，其制备方法，以及单独或组合使用它们来治疗和/或预防疾病，以及使用它们来生产用于治疗和/或预防疾病的药物，特别是用于治疗和/或预防心血管疾病的药物。
• [EN] 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES<br/>[FR] BENZAMIDES À SUBSTITUTION 1,3-THIAZOL-2-YL
  申请人：EVOTEC AG

  公开号：WO2016091776A1

  公开（公告）日：2016-06-16

  The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.

  本发明涉及一般式（I）所述和定义的1,3-噻唑-2-基取代苯甲酰胺化合物，以及包含所述化合物的药物组合物和药物组合物的用途，用于制造用于治疗或预防疾病的药物组合物，特别是神经源性疾病，作为唯一药剂或与其他活性成分组合使用。
• Bicyclic aza heterocycles, and use thereof
  申请人：Follmann Markus

  公开号：US09096592B2

  公开（公告）日：2015-08-04

  The present application relates to novel bicyclic azaheterocycles, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of cardiovascular disorders.

  本申请涉及新型双环氮杂杂环化合物，其制备过程，其单独或组合使用用于治疗和/或预防疾病，以及其用于制备治疗和/或预防疾病的药物，特别是用于治疗和/或预防心血管疾病。
• 1,3-thiazol-2-yl substituted benzamides
  申请人：BAYER AKTIENGESELLSCHAFT

  公开号：US10174016B2

  公开（公告）日：2019-01-08

  The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.

  本发明涉及本文所描述和定义的通式（I）的 1,3-噻唑-2-基取代苯甲酰胺化合物，涉及包含上述化合物的药物组合物和组合物，以及使用上述化合物制造药物组合物，用于治疗或预防疾病，特别是神经源性失调，作为单独制剂或与其他活性成分组合使用。
• BICYCLISCHE AZA-HETEROCYCLEN UND IHRE VERWENDUNG
  申请人：Bayer Intellectual Property GmbH

  公开号：EP2611802A1

  公开（公告）日：2013-07-10